NeuroDynamics Global Inc

NeuroDynamics Global Inc manufactures and distributes an FDA-cleared Class II neuromodulation medical device for the treatment of painful diabetic neuropathy (PDN). The company's primary offering is a minimally invasive, temporary-wear neuromodulation system delivered through a 20-day in-office protocol designed to reduce chronic neuropathic pain associated with diabetes. The device represents a non-pharmacologic, non-opioid alternative to conventional pain management approaches. NeuroDynamics operates a turnkey provider program that includes comprehensive training, clinical liaison support, revenue cycle management, reimbursement navigation, and outcomes tracking tools. The therapy is positioned for multi-specialty adoption across neurology, pain management, endocrinology, and primary care settings. The company manages insurance coverage coordination and payer-specific reimbursement processes. Manufacturing and regulatory compliance meet FDA Class II standards for neuromodulation devices. The operational model emphasizes rapid practice integration, with providers able to begin treating PDN patients within weeks of program enrollment. The device is indicated for durable pain relief in diabetic neuropathy patients and is covered by many insurance plans, though coverage remains payer- and patient-specific.